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ABSTRACT
MITOCHONDRIA IMAGING AND
TARGETED CANCER TREATMENT
by
Tinghan Zhao
Mitochondria are essential organelles as the site of respiration in eukaryotic cells and are
involved in many crucial functions in cell life. Dysfunction of mitochondrial metabolism
and irregular morphology have been frequently found in human cancers. The capability
of imaging mitochondria as well as regulating their microenvironment is important both
scientifically and clinically. Mitochondria penetrating peptides (MPPs), certain peptides
that are composed of cationic and hydrophobic amino acids, are good candidates for
mitochondria targeting. Herein, a novel MPP, D-argine-phenylalanine-D-arginephenylalanine-D-argine-phenylalanine-NH2 (rFrFrF), is conjugated with a rhodaminebased fluorescent chromophore (TAMRA). The TAMRA-rFrFrF probe exhibits
advantageous properties for long-term mitochondria tracking of up to three days with low
cytotoxicity and high biocompatibility. Mitochondria isolation experiments further
confirmed the mitochondria targeting of the TAMRA-rFrFrF probe with minimal
perturbation of mitochondrial function.
Mitochondrial function and metabolism are centrally involved in cancer initiation,
tumorigenesis, growth, survival, and metastasis. Dysfunction of mitochondria, especially
mitochondrial membrane hyperpolarization, plays a key role in drug resistance during
cancer treatment. We report a boron-dipyrromethene (BODIPY) triarylsulfonium-based
molecule (BD-PAG) as an opto-biomodulator (MOB) to target mitochondria and
modulate mitochondrial pH. Significantly, our BD-PAG MOB demonstrates the

reduction of drug resistance in cancer cell lines by regulating the mitochondrial pH and
depolarizing the mitochondrial membrane.
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CHAPTER 1
INTRODUCTION

1.1 Introduction of Mitochondria
1.1.1 Mitochondria
Mitochondria are double-membrane-bound essential organelles, serving as the site of
respiration within eukaryotic cells that generate ATP from energy-rich molecules.1
Mitochondrial structures are comprised of four compartments; outer membrane, inner
boundary membrane, intermembrane space, and matrix.2 The outer mitochondrial
membrane (OMM) is porous and freely traversed by ions and small molecules through
pore-forming membrane proteins (porins), that separates the inside of the organelle from
the cytoplasm. The inner mitochondrial membrane (IMM) possesses a several-fold larger
surface than the outer membrane, resulting in an invaginated membrane and the cristae
that

harbors

the

oxidative

phosphorylation

enzyme

complex.

The

oxidative

phosphorylation enzyme complex is a series of enzymes forming an electron transport
chain (ETC) to transfer electrons from electron donors to electron acceptors via redox
reactions, and couples this electron transfer with the transfer of protons across the
membrane to facilitate the synthesis of adenosine triphosphate (ATP).
Due to the porosity of OMM and the ion selectivity of ETC, an electrochemical
membrane potential of about -180 mV builds up across the inner mitochondrial
membrane. The mitochondrial matrix is more viscous than cytoplasm, and contains a
mixture of enzymes, special mitochondrial ribosomes, tRNA, and several copies of the
mitochondrial DNA genome. The major functions of enzymes present in the matrix are

1

oxidation of pyruvate and fatty acids, and the citric acid cycle, which is the synthesis of
ATP.3-9

Figure 1.1 Structure of mitochondria.
Source: Kühlbrandt, W. BMC Biol. 2015, 13, 89.

1.1.2 Morphology of Mitochondria
Mitochondrial morphologies vary widely in different cell types or cell conditions.
Fibroblast mitochondria, for example, are usually long filamentous-like, whereas
hepatocyte mitochondria are more uniformly punctate-like.10,

11

Their shapes change

continually through the combined actions of fission, fusion, and degradation.
Mitochondria are highly dynamic and can change in number and morphology within a
cell during development, the cell cycle, and even when exposed to various toxic
conditions. These dynamic processes are critical for maintaining a healthy functional
mitochondrial network.12, 13

2

Mitochondrial fission and fusion processes are both mediated by guanosine
triphosphatases (GTPases) in the dynamin family that divide and fuse the two lipid
bilayers that surround mitochondria.14 Fission is mediated by a cytosolic dynamin family
member (Drp1), recruited from the cytosol to form spirals around mitochondria that
constrict to sever both inner and outer membranes. Fusion between OMMs is mediated
by membrane-anchored dynamin family members Mfn1 and Mfn2, whereas fusion
between IMM is mediated by a single dynamin family member Opa1. 15-17 Mitochondrial
fission is critical for maintaining adequate mitochondria during cell growth and division.
Mitochondrial fusion is not essential for cell life, however it is essential for cell
development. 18, 19

Figure 1.2 Mitochondria fission and fusion.
Source: Sheridan, C.; Martin, S. J. Mitochondrion 2010, 10, 640-8.

3

1.2 Function of Mitochondria
1.2.1 Bioenergetic Metabolism
The most prominent roles of mitochondria are to produce the energy currency of the cell,
ATP, through respiration, and to regulate cellular metabolism. The main reactions
involved in ATP production are tricarboxylic acid (TCA) cycle, which occurs in the
mitochondrial matrix. Pyruvate is actively transported across the inner mitochondrial
membrane after undergoing glycolysis in the cytosol, and into the matrix where pyruvate
dehydrogenase facilitates its converse to acetyl-CoA. 20, 21
In the TCA cycle, the acetyl group of acetyl-CoA is transferred to oxaloacetate,
forming citrate. In a series of enzymatic steps, citrate is oxidized back to oxaloacetate,
with the excess carbon carried away as two molecules of carbon dioxide, and the
electrons removed in the process passed to the cofactors nicotinamide adenine
dinucleotide (NADH) and flavin adenine dinucleotide (FADH 2). Meanwhile the free
energy liberated is carried by NADH and FADH 2 to the mitochondrial ETC. All the
intermediates such as citrate, iso-citrate, alpha-ketoglutarate, succinate, fumarate, malate,
and oxaloacetate are regenerated during each turn of the cycle. 22, 23
In the ETC, electrons removed from the TCA cycle by NADH and FADH 2 are
used to power the pumping of protons from the matrix to the intermembrane space,
generating a potential difference across the inner mitochondrial membrane. This potential
difference is ultimately used to power the synthesis of ATP in the final step of oxidative
phosphorylation (OXPHOS).24, 25

4

Figure 1.3 Mitochondria TCA cycle.
Source: https://biochemistry3rst.wordpress.com/category/tca-etc/ accessed on 12/8/19

1.2.2 Regulation of Cell Death Signaling
Apoptosis is programmed cell death that occurs in multicellular organisms. Mitochondria
have been recognized as playing a central role in apoptotic cell death. 26, 27 The integrity
of the OMM is strictly regulated through interactions of members of the B-cell
lymphoma 2 (Bcl-2) protein family which is classified into two groups, pro-survival (BclxL, Bcl-w, A1 and Mcl-1) and pro-apoptotic (Bax, Bak, Bok, Bid, Bim, Bad, Noxa and
Puma). In the intrinsic (mitochondrial) pathway of apoptosis, pro-apoptotic stimuli such
as DNA damage lead to the activation of two key Bcl-2 family proteins, Bax and Bak.
Activation of Bax and Bak cause a reinforcement mitochondrial outer membrane
permeability (MOMP), which releases cytochrome c from intermembrane space into

5

cytoplasm where it promotes activation of a caspase cascade. 28-30 Once cytochrome c is
released into the cytoplasm, it binds with apoptotic protease activating factor – 1 (Apaf-1)
and ATP, which then binds to pro-caspase-9 to create a protein complex known as an
apoptosome. The apoptosome cleaves the pro-caspase-9 to its active form of caspase-9,
which in turn activates caspase-3 and 7 to complete the apoptotic process.31, 32
1.2.3 ROS Generation
Reactive oxygen species (ROS) are chemically reactive species containing oxygen, which
include peroxides, superoxide, hydroxyl radical, and singlet oxygen. ROS is formed as a
natural byproduct of the normal metabolism of oxygen, where mitochondrial ETC is one
of the major sites that generate ROS during the TCA cycle. Leakage of electrons at
complex I and complex III from ETC leads to partial reduction of oxygen to form
superoxide. Subsequently, superoxide is quickly dismutated to hydrogen peroxide by two
superoxide dismutases, then H2O2 is released to cytoplasm. Mitochondria also contain
antioxidant mechanisms to remove ROS. At low levels, ROS act as important signaling
molecules and potent mitogens, whereas higher levels can lead to pathological oxidative
damage to mitochondria and cells.33-35

1.3 Mitochondria and Cancer
Mitochondria are bioenergetic, biosynthetic, and signaling organelles whose dysfunction
of metabolism and/or morphology has been related to tumorigenesis, proliferation,
invasion, migration, and

metastasis.36 Cancer cells often exhibit fragmented

mitochondria, with high expression or enhanced activation of Drp1 and/or
downregulation of Mfn2, leading to constant mitochondrial fission. The mitochondrial

6

fission asymmetrically generates one depolarized and one hyperpolarized mitochondrion,
in which the hyperpolarized mitochondrion can be reintroduced into the healthy
mitochondrial network with reduced MOMP and apoptosis.37,

38

This mitochondrial

fragmentation is caused by an unlimited proliferation, resulting in an hypoxic
environment. Interestingly, hypoxia is considered a major driver of metabolic
reprogramming, cancer progression, and metastasis.39
In cancer cells, mitochondria play an alternative metabolism due to the hypoxia,
which cancer cells reprogram with the use of catabolic molecules, glucose and glutamine,
via signaling pathways containing known oncogenes, including Myc and tumor
suppressors. These signaling pathways regulate glucose toward aerobic glycolysis—the
so-called Warburg effect, and glutamine toward glutaminolysis for the purpose of
producing amino acids, nucleotides, and lipids that are essential for rapid proliferation. 40,
41

The altered metabolism of cancer cells raises the production of ROS, which are formed

as a signaling molecules to promote cell proliferation as mitogens.
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CHAPTER 2
MITOCHONDRIA PENETRATING PEPTIDE
FOR LIVE- CELL LONG-TERM TRACKING

Mitochondria are essential targets for treatment of diseases with mitochondrial disorders
such as diabetes, cancer, cardiovascular, and neurodegenerative disease. Mitochondria
penetrating peptides (MPPs) are composed of cationic and hydrophobic amino acids that
can target and permeate the mitochondrial membrane. With the objective of developing
new mitochondria penetrating peptides and long-term tracking of mitochondria, a novel
D-argine-phenylalanine-D-argine-phenylalanine-D-argine-phenylalanine-NH2

(rFrFrF)

peptide was conjugated with a rhodamine-based fluorescent chromophore, carboxytetramethylrhodamine (TAMRA). This

new probe (TAMRA-rFrFrF) exhibited

advantageous properties for long-term mitochondria tracking as demonstrated by
fluorescence microscopy and analyzed by the Pearson’s correlation coefficient. Cell
viability assays and oxygen consumption rates indicated low cytotoxicity and high
biocompatibility of the new contrast agent. Time dependent colocalization studies and
isolated mitochondria uptake measurement were performed with a long-term period,
which suggest that TAMRA-rFrFrF is a promising candidate for mitochondrial tracking
for up to 3 days.
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2.1 Introduction
Mitochondria are essential organelles as the site of respiration in eukaryotic cells and are
involved in multiple functions in cell life, such as energy supply, cell cycle and growth,
cell signaling pathways and apoptosis, cell proliferation, and metabolism. 42,

43

Meanwhile, these organelles are dynamic and continually undergo fusion, fission,
transport, and degradation. These processes are critical for maintaining a healthy,
functional mitochondrial network.44, 45 Dysfunctions of mitochondrial metabolism and/or
morphologies have been re-ported in human cancers as well as cardiovascular and
neurodegenerative diseases. Thus, the capability of monitoring mitochondrial
morphology is important in both scientific and clinical research. 46-48 However, due to
their continuously moving and changing morphology, monitoring mitochondria
morphological changes and dynamics over prolonged times is still difficult, and so far the
longest reported time for live cell mitochondria imaging is 24 h. 49, 50 Therefore, a longterm tracking strategy would be helpful for studying mitochondria morphology and
prospective drug delivery systems.
Over the last few decades, a variety of mitochondria targeting modules have been
developed. Most of those reported are delocalized lipophilic cations, which exhibit
relatively high toxicity to mitochondria.51, 52 Mitochondria penetrating peptides (MPPs)
represent a relatively new direction to develop mitochondria targeting vectors, which are
short peptides with high mitochondrial uptake. The structure of MPPs is generally
cationic and hydrophobic, which facilitates permeation through the hydrophobic
mitochondrial membrane and accumulation in the mitochondria matrix. 53-55 Due to their
primary peptide structures and bio-compatible properties, MPPs with short amino acid

9

sequences (fewer than 10 amino acids) are expected to exhibit low cytotoxicity, making
them promising candidates for the development of new probes for investigation of
mitochondria.56-58
Recently, MPPs were employed for targeting and delivering therapeutic cargos
into mitochondria with high efficiency.51, 53, 55-59 Peptides such as (FxrFxrFxr) (r is Dargine and Fx is cyclohexylalanine) exhibited low cytotoxicity and high mitochondria
targeting.57 Although numerous MPPs have been developed to deliver fluorescent dyes,
drugs and other cargos to mitochondria, there are no reports for long-term mitochondrial
tracking thus far, possibly due to their low serum stability. 60
Herein, we report a peptide containing six amino acid residues (Figure 2.1a), Dargine-phenylalanine-D-argine-phenylalanine-D-argine-phenylalanine-NH2

(rFrFrF),

conjugated to a rhodamine-derived fluorescent probe (TAMRA)61 (Figure 2.1b and
Figure 2.2), and studies of the resulting probe, TAMRA-rFrFrF, in time-dependent
mitochondria targeting and imaging. Unnatural D-arginine (r) in the first and third
positions was selected to provide positive charges, minimize amino peptidase
degradation, and increase serum-stability.62 The natural amino acid phenylalanine (F)
residue, which has a hydrophobic side group, was selected to tune the hydrophobicity and
impart low cytotoxicity. This prospective MPP sequence possesses three positive charges
with a balance of hydophilicity and hydrophobicity designed to reduce potential
disruptions to mitochondrial activity and maintain normal mitochondrial functions. 63, 64
Moreover, the amidated C-terminus was designed to increase structural stability and
attenuate hydrolysis.65
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Figure 2.1 Molecular structure and spectra. a) Molecular structure of unconjugated
rFrFrF, b) molecular structure of TAMRA, c) normalized absorption and emission
spectra of TAMRA-rFrFrF in PBS.

Figure 2.2 Molecular structure of TAMRA-rFrFrF and mitochondria penetration.
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2.2 Experimental Section
2.2.1 Material and Peptide Synthesis
All peptides and 6-(tetramethylrhodamine-5-(and-6)-carboxamido) hexanoic acid
conjugates

D-arginine-phenylalanine-D-arginine-

phenylalanine-

D-arginine-

henylalanine-NH2 (rFrFrF) (TAMRA-rFrFrF), following design in our lab, were
synthesized and purified by AnaSpec, EGT Corporation (Fremont, CA, USA). All other
chemical reagents were purchased from Fisher Scientific, and used as received unless
otherwise noted. Carbon dioxide (99.9% purity) was purchased from Airgas. All reagents
and solvents were purchased from commercial suppliers and used without further
purification.
2.2.2 Photophysical Properties Measurements
Linear absorption, fluorescence, and excitation spectra of TAMRA and TAMRA-rFrFrF
were investigated in PBS at room temperature. The absorption spectra were measured
with a Tecan Infinite M200 PRO plate reader spectrometer in 1 cm path length quartz
cuvettes. The fluorescence and excitation spectra were obtained using an Edinburgh
Instruments FLS980 fluorescence spectrometer.
2.2.3 Cell Culture
Human cervical cancer HeLa and pig normal kidney LLC-PK1 cell lines were cultured in
Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine
serum, 1% penicillin/streptomycin at 37 °C in a humidified 5% CO 2 incubator.
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2.2.4 Cell Viability
To assess the cytotoxicity of unconjugated-rFrFrF and TAMRA-rFrFrF, HeLa and LLCPK1 cells were cultured in DMEM cell medium supplemented with 10% fetal bovine
serum, 1% penicillin, and streptomycin at 37 °C and 5% CO 2 . Cells were placed in 96
well plates and incubated until there were no fewer than 5 × 10 3 cells per well for the
experiments. Next, cells were incubated with different concentrations of rFrFrF (1, 2.5, 5,
10, 20, 40, and 80 μM) and TAMRA-rFrFrF (1, 2.5, 5, 10, 20, 40, and 80 μM) for an
additional 22 h, where the values within parentheses refer to the nominal concentrations
of the peptides. After that, 20 μL of the CellTiter 96 Aqueous One solution reagent (for
MTS assay) was added into each well, followed by further incubation for 2 h at 37 °C.
Cytotoxicities of Mitotracker Green and Red was performed same procedure as
unconjugated-rFrFrF and TAMRA-rFrFrF in HeLa cells with a various concentration of
(0.1, 0.25, 0.5, 1, 2, 4, 8, and 16 μM).
The respective absorbance values were recorded with a Tecan Infinite M200 PRO
plate reader spectrometer at 490 nm. Cell viabilities were calculated on the basis of the
following equation,

Abs s 490 nm  Abs D 490 nm
Cell Viability  %  
100%
Abs c 490 nm  Abs D 2 490 nm

(2.1)

where Abss490nm is the absorbance of the cells incubated with different concentrations
of experimental probe solutions, AbsD490nm is the absorbance of cell-free well
containing only dye at the concentration that was studied, Absc490nm is the absorbance
of cells alone incubated in the medium, and AbsD2490nm is the absorbance of the cellfree well.
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2.2.5 Oxygen Consumption Rate (OCR) Measurement
Oxygen consumption rates were measured for HeLa cells by using Seahorse XFe96
Analyzer (Agilent, Santa Clara, CA, US). HeLa cells were placed in 96 well Seahorse
XF96 cell culture plates at a density of 2 × 10 4 cells/well, and incubated DMEM
supplemented with 10% fetal bovine serum, 1% penicillin, and streptomycin at 37 °C and
5% CO2 for 16 h. Next, to the cells were added 5μM TAMRA-rFrFrF (in 1mM DMSO
stock solution) for 6 h. A negative control was treated with DMSO only. After washing
out TAMRA-rFrFrF, cells were incubated with XF Assay Medium for 1 h. Measurement
of OCR was performed at baseline and following sequential injections of a) 1 μM
oligomycin, (final conc. 0.8 μg/mL) (20 μL of 10 drops), an ATP synthase inhibitor, b)
final conc. 2 μM FCCP (22 μL of 10 drops), a mitochondrial uncoupler, and c) 0.5 μM
Rotenon + 0.5 μM antimycin A, (25 μL of 10 drops), a complex III and complex I
inhibitor, respectively. This enabled the measurement of the OCR coupled to ATP
production, as well as the maximal and the mitochondrial OCR, respectively. 66

2.2.6 Colocalization Study
To investigate the efficiency and specificity of TAMRA-rFrFrF, HeLa and LLC-PK1
cells were employed. All cells were seeded on confocal dish (MatTek) at the density of 4
× 104 cells per dish and incubated for 24 h at 37 °C. Stock solutions of TAMRA, rFrFrF,
and TAMRA-rFrFrF dissolved in DMSO were prepared at a nominal concentration of 10 4
μM. The stock solution was diluted to 5 μM with the DMEM respectively and freshly
placed over cells for a 1.5 h incubation period. Cells were washed three times with PBS
and then post-incubated with fresh medium at 37 °C for various time periods (0 h, 1 h, 2
h, 3 h, 4 h, 6 h, 8 h, 12 h, 18 h, 1 d, 2 d, and 3 d). After post-incubation, cells were further
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incubated with MitoTracker Green (MT Green)， Lysotracker Green (LT Green), or ERtracker Green (ER Green) separately before cell imaging. 67 Cells were then washed with
PBS three times, and then the live cell imaging solution (Molecular Probes) was added to
confocal dishes. Fluorescence images were obtained using an inverted Olympus IX70
microscope coupled with a FITC filter cube (Ex: 482/40; DM: 506; Em: 534/40) for MT
green, LT green, or ER Green, and a Texas Red filter cube (Ex: 562/40; DM: 593; Em:
624/40) for TAMRA or TAMRA-rFrFrF, respectively. Pearson’s correlation coefficients
for TAMRA and TAMRA-rFrFrF were calculated using Fiji, a freely available image
processing software.
To further compare long-term tracking advantage of TAMRA-rFrFrF, incubation
time-dependent cell imaging of MT green was performed in HeLa cells. Cells were
incubated with 100 nM of MT green for 15 min at 37 °C. Cells were washed three times
with PBS and then post-incubated with fresh medium at 37 °C for various time periods (0
h, 1 h, 2 h, 4 h, 6 h and 12 h). After post-incubation, cells were further incubated with
100 nM of Hoechst 33258 for 10 min and washed out with PBS before cell imaging.

2.2.7 Mitochondria Uptake Measurement
To evaluate the uptake of TAMRA-rFrFrF by mitochondria, 1×106 cells were incubated
with 5 μM TAMRA-rFrFrF for 1.5 h at 37 °C. After washing twice with PBS, postincubation was performed at 37 °C for 2 h, 4 h, 6 h, 12 h, 1 d, 2 d, and 3 d. Subsequently,
mitochondria were extracted according with a Mitochondria Isolation Kit for cultured
cells (Thermo Fisher Scientific, Waltham, MA, US), and diluted to 2 mL using PBS. The
fluorescence intensity was measured using an Edinburgh Instruments FLS980
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fluorescence spectrometer. Isolated mitochondria with no TAMRA-rFrFrF treatment
served as the blank.

2.3 Results and Discussion
2.3.1 Cell Viability
The cytotoxicity and bio-compatibility of rFrFrF and TAMRA-rFrFrF were evaluated in
HeLa and pig kidney (LLC-PK1) cells via an MTS assay (Figure 2.3 and Figure 2.4). 68
The peptide rFrFrF itself did not show any acute toxic effects over a range of
concentrations, even at the highest concentration employed of 80 μM, cell viability
remained at 100% after 24 h incubation. The TAMRA-rFrFrF probe also exhibited very
good cell viability with a 90% survival rate at concentrations up to 80 μM after 24 h.
Meanwhile, commercial Mitotracker Green and Red were evaluated in HeLa cells to
compare the cytotoxicity with rFrFrF and TAMRA-rFrFrF (Figure 2.5). Mitotracker
Green appears to be more toxic at concentrations over 8 μM, while MitoTracker Red
exhibits high cytotoxicity at 4 μM with only 30% of cells alive after 24 h incubation.

Figure 2.3 Cell viability of HeLa cells after treatment with TAMRA-rFrFrF and
unconjugated rFrFrF at different concentrations. HeLa cells with no treatment was
classified as 100%.
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Figure 2.4 Cell viability of LLC-PK1 cells after treatment with TAMRA-rFrFrF and
unconjugated rFrFrF at different concentrations. LLC-PK1 cells with no treatment was
classified as 100%.

Figure 2.5 Cell viability of HeLa cells after treatment with Mitotracker Green and Red at
different concentrations. HeLa cells with no treatment were classified as 100%.
2.3.2 Cellular Uptake and Colocalization
The use of the new MPP probe, TAMRA-rFrFrF, was then investigated as a
mitochondrial-targeting agent by fluorescence imaging and colocalization studies. Three
experimental groups were conducted, including TAMRA-rFrFrF, TAMRA, and TAMRA
physically mixed with unconjugated rFrFrF. After 1.5 h incubation with one of the
aforementioned reagents with either HeLa or LLC-PK1 cells, the culture media was
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changed to pure Dulbecco’s Modified Eagle Medium (DMEM) and the HeLa cells were
further incubated for 1 d.
As shown in Figure 2.6, bright fluorescence was observed for cells incubated with
TAMRA-rFrFrF. By contrast, no fluorescence was detected for the other two groups
(TAMRA and TAMRA mixed with unconjugated rFrFrF). Furthermore, TAMRA-rFrFrF
displayed a high level of selectivity for mitochondria targeting, with a Pearson’s
correlation coefficient value of 0.88 relative to MitoTraker Green, a commercial
mitochondrial staining agent while unconjugated TAMRA itself and the physical mixture
of TAMRA with rFrFrF exhibited no mitochondria targeting ability nor capability of
being uptaken by cells.69

Figure 2.6 Cellular uptake imaging. HeLa cells were incubated with 5 μM of TAMRA,
TAMRA mixed with unconjugated rFrFrF and TAMRA-rFrFrF separately for 1.5 h, and
after washing, additional incubation of the cells at 37 °C for 1 d (post-incubation time). a)
HeLa cells treated with TAMRA, b) HeLa cells treated with TAMRA mixed with
unconjugated rFrFrF, c) HeLa cells treated with TAMRA-rFrFrF.
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To further evaluate mitochondrial selectivity, TAMRA-rFrFrF colocalization
studies with Lysotracker Green and endoplasmic reticulum (ER-tracker Green) were also
performed with HeLa cells. Poor co-localization was observed between TAMRA-rFrFrF
with Lysotracker Green or ER-tracker Green, in which Pearson’s values are less than 0.4
(Figures 2.7 and 2.8). Thus, the designed rFrFrF sequence is attributed for successful cell
uptake and high selectivity for mitochondrial targeting.

Figure 2.7 Colocalization of LT Green. HeLa cells were incubated with 5 μM TAMRArFrFrF for 1.5 h, and, after washing out the TAMRA-rFrFrF, an extra incubation of the
cells at 37 °C for various times (post-incubation time). Then, cells were incubated with
200 nM of Lysotracker Green for 1 h and washed out before cell imaging. Pearson's
Value is labeled as R.
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Figure 2.8 Colocalization of ER Green. HeLa cells were incubated with 5 μM TAMRArFrFrF for 1.5 h, and, after washing out the TAMRA-rFrFrF, an extra incubation of the
cells at 37 °C for various times (post-incubation time). Then, cells were incubated with 1
μM of ER-tracker Green for 30 min and washed out before cell imaging. Pearson's Value
is labeled as R.

2.3.3 Time Dependent Colocalization
To better understand the time dependent mitochondrial uptake of TAMRA-rFrFrF, timedependent cell imaging experiments were conducted. In general, after incubation with
TAMRA-rFrFrF for 1.5 h, after washing, HeLa or LLC-PK1 cells were then incubated in
cell medium alone for various times (post-incubation time) before cell imaging for long
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term mitochondria tracking was performed. Cells that underwent 0 to 4 h post-incubation
(Figures 2.9 and 2.10) displayed strong fluorescence, however, mitochondria targeting
was less efficient at these time points, which may be related to the charge and
hydrophobicity

of

TAMRA-rFrFrF.

The

mitochondrial

membrane

exhibits

hydrophobicity and a potential difference in which the inner mitochondrial membrane is
negatively charged and outer membrane is positively charged.53, 54, 70 MPPs that possess
positive charges and hydrophobicity tend to target and penetrate the mitochondria
membrane more easily.56 However, increasing peptide charge or hydrophobicity may
increase mitochondrial disruptive activity and lead to unwanted side effects and
toxicity.63, 64
We discovered that our MPP could slowly but effectively target mitochondria. As
shown in Figures 2.9, 2.10, 2.11 and 2.12, TAMRA-rFrFrF largely permeated
mitochondria after 6 h of post-incubation time. Moreover, cells still exhibited significant
fluorescence in mitochondria even at 3 d of post-incubation. By comparison Mitotracker
Green was not capable of tracking mitochondria reliably much longer than 6 h (Figure
2.11). These results clearly demonstrating long-term mitochondria tracking ability of the
new MPP probe.
Mitochondria are highly dynamic organelles that constantly undergo fission,
fusion and degradation,71 e.g., HeLa cells undergo 1.44 events/min of fission. 72 These
constant changes cause asymmetrical distribution of matrix proteins in the daughter
mitochondria.73,

74

In our study, TAMRA-rFrFrF exhibited persistent localized

mitochondria staining ability without significant depletion or leakage over the 3 d postincubation period, an assertion that was quantitatively confirmed by the Pearson's
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correlation coefficient values (Figure 2.12b), indicating TAMRA-rFrFrF is capable of
mitochondria targeting under frequent fission and fusion events.

22

Figure 2.9 Time dependent HeLa cell colocalization. HeLa cells were incubated with 5
μM TAMRA-rFrFrF for 1.5 h, and, after washing out the TAMRA-rFrFrF, an extra
incubation of the cells at 37 °C for various times (post-incubation time). Then, cells were
incubated with 100 nM of Mitotracker Green for 15 min and washed out before cell
imaging. Pearson's Value is labeled as R.
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Figure 2.10 Time dependent LLC-PK1 cell colocalization. LLC-PK1 cells were
incubated with 5 μM TAMRA-rFrFrF for 1.5 h, and, after washing out the TAMRArFrFrF, an extra incubation of the cells at 37 °C for various times (post-incubation time).
Then, cells were incubated with 100 nM of Mitotracker Green for 15 min and washed out
before cell imaging. Pearson's Value is labeled as R.
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Figure 2.11 Time dependent MT-Green cell imaging. HeLa cells were incubated with
100 nM Mitotracker Green for 15 min, and, after washing out Mitotracker Green, an
extra incubation of the cells at 37 °C for various times (post-incubation time). Then, cells
were incubated with 100 nM of Hoechst 33258 for 10 min and washed out before cell
imaging. Pearson's Value is labeled as R.
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Figure 2.12 Time dependent cell imaging. a) HeLa cells were incubated with 5 μM of
TAMRA-rFrFrF for 1.5 h, and after washed out the TAMRA-rFrFrF an extra incubation
of the cells at 37 °C for various times (post-incubation time). Then, cells were incubated
with Mitotracker Green for 15 min and washed before cell imaging. Pearson's value is
labeled as R. b) Post-incubation time dependent Pearson's correlation coefficient of HeLa
cells.

27

2.3.4 Isolated Mitochondria Uptake
To further confirm the mitochondria targeting ability of TAMRA-rFrFrF, mitochondria
were isolated from TAMRA-rFrFrF treated cells and fluorescence intensities were
recorded with a fluorescence spectrometer.75 The fluorescence intensities of isolated
mitochondria with 6 h, 12 h, 1 d, 2 d, and 3 d post-incubation were unquestionably much
more intense than those of the blank - isolated untreated mitochondria (Figure 13 and
Figure 14 ). These results clearly demonstrate that the uptake of TAMRA-rFrFrF is timedependent and appears rather efficient. There was no intensity decrease of TAMRArFrFrF in mitochondria upon prolonged incubation. In fact, the post-incubation time was
a key factor for TAMRA-rFrFrF to accumulate in the mitochondria in HeLa cells.
Further, the mitochondria present a whole set of complex proteolytic enzyme
systems that regulate mitochondrial function and activities. Especially for mitochondrial
degradation,76,

77

endogenous proteases are responsible for the degradation of their

internal proteins, which are eventually shuttled back to the cytoplasm by a specific
peptide transporter.78, 79 The fluorescence intensity of TAMRA-rFrFrF did not decrease
from 12 h to 3 d, which indicated TAMRA-rFrFrF underwent no apparent release to the
cytoplasm and was proteolytically stable. Overall TAMRA-rFrFrF is capable of longterm mitochondrial tracking up to 3 d, with high stability and selectivity.
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Figure 2.13 HeLa cells mitochondria uptake TAMRA-rFrFrF measurement. 5 μM of
TAMRA-rFrFrF was pre-incubated with HeLa cells for 1.5 h, followed by washing out
TAMRA-rFrFrF and post-incubation of the HeLa cells for 2 h, 4 h, 6 h, 12 h, 1 d, 2 d, and
3 d. Isolated mitochondria from untreated cells were the blank (N = 3).
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Figure 2.14 LLC cells mitochondria uptake TAMRA-rFrFrF measurement. 5 μM of
TAMRA-rFrFrF was pre-incubated with LLC cells for 1.5 h, followed by washing out
TAMRA-rFrFrF and post-incubation of the LLC cells for 2 h, 4 h, 6 h, 12 h, 1 d, 2 d, and
3 d. Isolated mitochondria from untreated mitochondria cells were the blank. (N=3).
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2.3.5 Oxygen Consumption Rate (OCR)
To probe mitochondria function of cells incubated with TAMRA-rFrFrF, oxygen
consumption rates were measured in HeLa cells using a Seahorse analyzer. 80 The results
demonstrated that the basal respiratory rate and maximal respiratory capacity (Figure
2.15) decreased somewhat in the TAMRA-rFrFrF treated vs. untreated HeLa cells.
Although decreases in maximum respiratory capacity and basal respiratory rate are strong
indicators of potential mitochondrial dysfunction,81 in this situation, the decreases are
most likely a result of a change in the potential difference of outer and inner
mitochondrial membranes caused by the cationic rFrFrF rather than mitochondrial
dysfunction.81, 82 The drop of mitochondrial membrane potential difference will inhibit
the activity of electron transport chain, which would decrease maximum respiratory
capacity and basal respiratory rate.83, 84 Furthermore, spare respiratory capacity exhibited
only a slight decrease while ATP production underwent no significant reduction when
compared with a control, indicating the TAMRA-rFrFrF probe has minimal influence on
mitochondrial respiration.85 In fact, the results indicated that mitochondrial functions
were mostly unchanged.

Figure 2.15 Oxygen consumption rates. a) Oxygen consumption rates (OCR) in
TAMRA-rFrFrF treated vs. untreated HeLa cells (blank, n = 5). OCR was measured
approximately every 8 min using an XF-96 analyzer as described in the Supporting
Information Methods section. b) The rates of basal respiration, maximal respiratory
capacity, spare respiratory capacity, and ATP-linked respiration (ATP production).
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2.4 Conclusion
In conclusion, a novel MPP probe, TAMRA-rFrFrF, was designed that contained 6 amino
acid residues. Our investigations demonstrated the new MPP probe’s utility in long-term
in vivo mitochondrial tracking for up to 3 d, which is far superior to commercial
Mitotracker Green and Red. Importantly, the TAMRA-rFrFrF probe can undergo
mitochondria distribution, activities, and fission or fusion events with no degradation or
transportation by mitochondria proteolysis, which fulfills major criteria for long-term
mitochondria tracking. In addition, we have shown that the TAMRA-rFrFrF was
essentially benign and biocompatible from cell viability and oxygen consumption rate
experiments. There is an important link between mitochondrial morphology change and
mitochondrial dysfunction,47, 86-88 in which mitochondrial morphology serves as a marker
to study and treat mitochondria dysfunction related disease. Therefore, this TAMRArFrFrF MPP probe is a potential candidate for live cell mitochondrial morphological and
mitochondrial dysfunction studies.
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CHAPTER 3
MITOCHONDRIAL PH REGULATING AND THE ROLE
IN REDUCING DRUG RESISTANCE

Mitochondrial membrane polarization (mitochondrial membrane potential difference) is
formed by the membrane proton gradient, which plays a key role in chemoresistance due
to the hyperpolarization of mitochondrial membrane in cancer cells. Herein, we
hypothesize that regulating mitochondrial pH to depolarize the mitochondrial membrane
in cancer cells may offer a potential therapeutic strategy to counter certain
chemotherapeutic drug resistance.
A BODIPY chromophore based triarylsulfonium photoacid generator (BD-PAG) was
designed and synthesized to target mitochondria with the aim to regulate mitochondrial
pH. Cell viability assays demonstrate the relatively low toxic and biocompatibility of
BD-PAG. To determine the BD-PAG capabilities, examination of cellular distribution
was evaluated in HeLa and MCF-7 cell lines, demonstrating the selective localization of
BD-PAG in mitochondria as evidenced by high Pearson’s colocalization coefficients
when co-incubated with commercial mitotracker probes. Investigation of mitochondrial
pH and assay of membrane potential indicated BD-PAG is capable of regulating
mitochondrial pH, which reduces the membrane potential. Time lapse, Z-stack images
and caspase assays further demonstrated the membrane potential change via pH
regulation. Further experiments demonstrated their use in against anti-cancer drug
resistance, all described below.
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3.1 Introduction
Mitochondria are essential organelles as they are the site of respiration and are composed
of a double-membrane in eukaryotic cells, and involved in many essential cellular
functions, including energy supply, cell cycle and growth, cell signaling pathways,
apoptosis, and metabolism.89 The mitochondrial outer membrane (OMM) and inner
membrane (IMM) are composed of phospholipid bilayers, which harbor electron
transport chain complexes (ETC).90 ETC use electron flow to pump protons (H +) into the
intermembrane space to generate a proton gradient that drives the synthesis of adenosine
triphosphate (ATP), and, furthermore, create a potential force (mitochondrial membrane
polarization) represented by the mitochondrial membrane potential (Δᴪ ~ -150 to -180
mV).91-94 More important, the disturbed Δᴪ in dysfunctional mitochondria may be related
to multiple diseases, especially cancer. 95-97
It was found that mitochondrial membrane hyperpolarization contributes to
greater migration and invasion of cancer cells while the Δᴪ is as low as -220 mV, due to
the ETC functional status.98 Moreover, the change of membrane polarization has direct
impact on mitochondrial outer membrane permeabilization (MOMP). 99,

100

MOMP

constitutes a decisive step in apoptosis (a form of programmed cell death), regulating
cytochrome C release and activating caspase cascade.101 Most cancer treatments,
including chemotherapy, radiation therapy and immunotherapy, aim

to trigger

apoptosis.102, 103 However, MOMP is significantly reduced in cancer cells due to the low
Δᴪ, and this a major source of drug resistance in cancer treatment. 104,

105

Hence,

regulating Δᴪ in cancer cells may offer a potential therapeutic strategy to overcome drug
resistance.
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Drug resistance remains a persistent problem in treating cancer with inhibition of
apoptosis pathway becoming more prevalent.106, 107 However, most of studies focus on
the upper stream of the apoptosis pathway, such as the Bcl-2 protein family expressing
regulation.108-110 So far, there has been no literature reports of regulating the
mitochondrial pH to overcome drug resistance, by virtue of the lack of strategies to target
mitochondrial and introduce acid effectively.
Triarylsulfonium based photoacid generators (PAGs) are light-sensitive organic
compounds that can produce proton (H+) upon exposure to certain wavelengths of
light.111 Lipophilic cationic properties of triarylsulfonium salts are similar to triphenyl
phosphonium (TPP) salts, a frequently used mitochondria targeting moiety, and make it a
promising candidate to target mitochondria.112,

113

Herein, we designed a visible light

absorbing BODIPY chromophore-based triarylsulfonium (BD-PAG) (Figure 3.1) to
target

mitochondria.IN

the

electronically

excited

state,

energy

transfers

to

triarylsulfonium moiety to facilitate homolytic cleavage of a C-S bond, formating a
cation-radical on the sulfur-containing fragment, and, after hydrogen atom abstraction,
form H + to regulate mitochondrial pH.114 This is the first report of a PAG to regulate
mitochondrial pH to depolarize the mitochondrial membrane and attenuate cancer drug
resistance.

Figure 3.1 Molecular structure and spectra. a) Molecular structure of BD-PAG,
b) normalized absorption and emission spectra of BD-PAG.
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3.2 Results and Discussion
3.2.1 Cell Viability
The cytotoxicity and bio-compatibility of BD-PAG in dark were evaluated in HeLa and
MCF-7 cells via an MTS assay.115 BD-PAG did not present any acute toxic effects over a
range of concentrations, even at the highest concentration employed (80 μM), cell
viability remained over 90% in the dark (Figure 3.2). Irradiation time-dependent cell
viability was performed after incubation with BD-PAG for 4 h (to ensure cellular uptake),
then BD-PAG was removed (washed away), and normal cell medium was introduced
followed by LED light (Thorslab, 80 mW/cm2) illumination of various times in both cell
lines (Figure 3.3 and Figure 3.4). Only a slight toxicity of BD-PAG was observed after
20 min light irradiation in at a concentration of 20 μM, where the cell viability was
around 80%. Control group without BD-PAG but LED light showed no toxicity to the
cell.

Figure 3.2 Dark cell viability. Cell viability of HeLa and MCF-7 cells treated with 1 μM
to 80 μM of BD-PAG at 37 °C for 24 h separately. Untreated cells were classified as
100% cell viability. (N=6)
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Figure 3.3 Irradiation time dependent cell viability of HeLa cells after treatment with 10
and 20 μM of BD-PAG for 4 h. Blank is HeLa cells with no treatment. HeLa cells with
no irradiation and treatment classified as 100%.(N=6)

Figure 3.4 Irradiation time dependent cell viability of MCF-7 cells after treatment with
10 and 20 μM of BD-PAG for 4 h. Blank is MCF-7 cells with no treatment. MCF-7 cells
with no irradiation and treatment classified as 100%.(N=6)
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3.2.2 Cellular Uptake and Colocalization
For demonstration purposes, fluorescence imaging was performed in the human cervical
cancer cell line, HeLa, with BD-PAG. From the basic cell viability test results, 2 μM of
BD-PAG was employed for cell incubation and fluorescence imaging. Cells treated with
BD-PAG for 30 min displayed strong fluorescence upon excitation, manifesting the good
biological compatibility of BD-PAG and the capability of cell uptake by (Figure 3.5).

Figure 3.5 Cellular uptake image. HeLa cells were incubated with 2 μM of BD-PAG at
37 °C for 1 h, cell imaging was performed after washed with PBS. Texas Red filter cube
(Ex: 562/40; DM: 593; Em: 624/40) for BD-PAG
To confirm the assumption that the triarylsulfonium salt should have
mitochondria targeting ability due to the similar lipophilic cationic property as TPP, the
localization of BD-PAG in cells was monitored by confocal microscopy. In the
experiment, colocalization studies were performed with MitoTracker Green, LysoTracker
Green, and ER-Tracker Green and fluorescent images were captured (Figures 3.6 and
3.7). Fluorescence from BD-PAG was observed, and the distribution colocalized very
well with MitoTracker Green in both HeLa and MCF-7 cell lines. In addition, Pearson’s
correlation coefficient values suggest that BD-PAG exhibits a strong selectivity for
mitochondria in various concentration of BD-PAG (Pearson’s value ~ 0.9), while no
selective localization to lysosomes or endoplasmic reticulum (ER) was observed, as
evidenced by Pearson’s values less than 0.3.

38

Figure 3.6 Colocalization of BD-PAG in HeLa cells. HeLa cells were incubated with 2
μM of BD-PAG at 37 °C for 30 min followed by colocalization stains, a) 100 nM of
MitoTracker Green was incubated with cells for 15 min. b) 400 nM of LysoTracker
Green was incubated with cells for 1 h. c) 1 μM of ER-Tracker Green was incubated with
cells for 30 min. Pearson's values are labeled as R.

Figure 3.7 Colocalization of BD-PAG in MCF-7 cells. MCF-7 cells were incubated with
2 μM of BD-PAG at 37 °C for 30 min, 100 nM of MitoTracker Green was incubated with
cells for 15 min before the cell imaging. Pearson’s value R = 0.97
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3.2.3 Mitochondrial pH
To ascertain the mitochondrial pH regulating efficiency of BD-PAG, mitochondrial pH
was measured by a pH-sensitive ratiometric fluorescent indicator, carboxy SNARF-1
AM, at various irradiation times of cells incubated with BD-PAG, using a fluorescence
plate reader.116, 117 The fluorescence intensities of carboxy SNARF-1 AM were measured
at 590 nm and 650 nm. The data was plotted as a ratio of the emission intensities at 650
nm/590 nm (Figure 3.8), where the emission at 650 nm decreased with decreasing pH.118
The results exhibited a significant decrease of 650 nm/590 nm emission intensity
ratio after the LED light irradiation, implying a mitochondrial pH decrease. This indicates
that BD-PAG, under irradiation, is capable of generating H + that consequently lowers the
mitochondrial pH. Meanwhile, the decrease of mitochondrial pH is dependent on both
BD-PAG concentration and irradiation time. The decreasing ratio of 20 min irradiation of
20 μM of BD-PAG indicates a 0.8 to 1.0 pH drop compared to the control group (Figure
3.8).119, 120

Figure 3.8 Mitochondrial pH in HeLa cell. HeLa cells were incubated with with 10 and
20 μM of BD-PAG for 4 h. The fluoresent of 590 nm and 650 nm were measured by
plate reader at 488 nm excitation. Control group is HeLa cells with no BD -PAG
treatment (N=5).
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3.2.4 Mitochondrial Membrane Potential
To analyze the relevance of BD-PAG regulated mitochondrial pH with mitochondrial
membrane potential change, the JC-1 mitochondrial membrane potential assay was
performed. The fluorescence intensities of JC-1 at 530 nm and 590 nm were record as a
ratio of 590 nm/530 nm emissions (Figure 3.9). JC-1 aggregates (emits at 590 nm) imply
hyperpolarization of mitochondrial membrane, which increases Δᴪ, while the
depolarization of mitochondrial membrane (decrease of Δᴪ) is due to the JC-1 monomer
(emits at 530 nm).121 The JC-1 measurement results were consistent with mitochondrial
pH changes. Moreover, the lipophilic cationic BD-PAG itself shows no impact to the
membrane potential in the dark. This result indicates the mitochondrial membrane
depolarization was caused by H + release from BD-PAG upon irradiation, acidifying the
mitochondria is was capable of regulating the proton gradient that drives mitochondrial
membrane depolarization.122

Figure 3.9 Mitochondrial membrane potential in HeLa cell. HeLa cells was incubated
with 10 and 20 μM of BD-PAG for 4 h. The fluoresent of 530 nm and 590 nm were
measured by plate reader at 475 nm excitation. Control group is HeLa cells with no BDPAG treatment. HeLa cells with no irradiation and treatment was classified as
100%.(N=6)
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3.2.5 Irradiation Time-Dependent Time-Lapse Cell Imaging
Irradiation time-dependent time-lapse cell imaging was performed in HeLa cells to
observe the mitochondrial morphology change under the photo-triggered H + release.
Cells incubated with BD-PAG were irradiated with laser light directly by the fluorescent
microscope (prox. Power density ~4.9 W/cm2) from 0 to 50 s with a PAG concentration
of 10 and 20 μM, separately (Figures 3.10 and 3.11, respectively). Interestingly, the timelapse images exhibit a filamentous to punctate mitochondrial dynamic transition during
the light irradiation.

Figure 3.10 20 µM of BD-PAG treated time lapse cell imaging. HeLa cells were treated
with 20 µM of BD-PAG for 30 min. After washed out BD-PAG, time lapse cell imaging
was captured every 10 s.
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Figure 3.11 Time lapse and Z-stack cell imaging. a) Time lapse cell imaging of HeLa
cells treated with 10 µM of BD-PAG. After washed out BD-PAG, time lapsed cell
images were captured every 10 s while the cells were under irradiation in the whole
course. 3D image captured by confocal microscope before b) and after c) 50 s of light
irradiation.
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Furthermore, the Z-stack of the starting time point and irradiation ending time
point cell images (Figure 3.11b and c) present a significant mitochondrial morphology
difference, displaying that most of the mitochondria transformed from the filamentouslike to punctate-like morphology after 50 s. Although the mitochondrial morphology
appears to be diverse, especially in cancer cells,123 this phenotypic change from
filamentous to punctate has been shown to be intimately involved in apoptosis under
stressful conditions.124-126 This transition may be caused by the MOMP increase and
apoptosis initiation, which is induced by mitochondrial membrane depolarization. This
set of data further supports the potential of photo-triggered BD-PAG to regulate
mitochondrial pH and depolarize the mitochondrial membrane.

3.2.6 Caspase 3/9 Assay
To further evaluate BD-PAG-regulated depolarization and the MOMP reinforcement,
caspase 3/9 assays were performed in HeLa cells. Cytochrome c is the key protein to
initiate the intrinsic apoptosis pathway that is localized in the compartment between the
inner and outer mitochondrial membranes.127,
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The reinforced MOMP leads

cytochrome c to be released from the mitochondrial membrane, resulting in a caspase
cascade that activates caspase 9, then, in turn, caspase 9 activates caspase 3 and 7 to
induce cell apoptosis.129 Both caspase 3 and 9 exhibited a strong increase after light
irradiation (Figure 3.12), while the group of BD-PAG with no irradiation (kept in the
dark) showed no significant difference relative to the blank. This downstream apoptosis
pathway activation provides confirmation of cytochrome c release from mitochondria,
and support of the occurrence for mitochondrial membrane depolarization and MOMP
reinforcement.
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Figure 3.12 Irradiation time dependent caspase 3/9 assay of HeLa cells treated with 10
µM of BD-PAG for 4 h. Blank group is HeLa cells with no BD-PAG. (N=3).

3.2.7 Combined Drug Therapy
The capability of photo-triggered H+ release from BD-PAG to overcome anti-cancer drug
resistance was examined by irradiation time-dependent combined drug therapy with
chlorambucil (Cbl). Anti-cancer drug Cbl is a potent alkylating agent that is primarily
used to treat chronic lymphocytic leukemia. Its drug resistant mechanism is due to the
tumor suppressor gene P53 mutation or under-expression, which inhibits the apoptosis
pathway and results in mitochondrial membrane hyperpolarization and MOMP
reduction.130-132 The cell viability of chlorambucil and/or BD-PAG were measured with
both HeLa and MCF-7 cell lines (Figures 3.13 and 3.14). In the BD-PAG and Cbl
combination therapy study, we found out the therapeutic efficiency of Cbl was
remarkably increased with PB-PAG upon light activation, and the IC50 of Cbl was
reduced to 5 μM when compared with the reported IC50 in HeLa and MCF-7 at 100
μM.133, 134 We reason that the photo-triggered BD-PAG caused mitochondrial membrane
depolarization and MOMP reinforcement attenuated drug resistance and significantly
enhanced the therapeutic efficiency of Cbl.
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Figure 3.13 Irradiation time dependent combined drug therapy on HeLa cells after
treatment with 5 μM of Cbl and BD-PAG in varied concentration. a) HeLa cells with 20
μM of BD-PAG upon LED light irradiation. b) HeLa cells with 10 μM of BD-PAG upon
LED light irradiation. HeLa cells with no irradiation and treatment classified as 100%.
(N=6).
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Figure 3.14 Irradiation time dependent combined drug therapy on MCF-7 cells after
treatment with 5 μM of Cbl and BD-PAG in varied concentration. a) MCF-7 cells with 20
μM of BD-PAG upon LED light irradiation. b) MCF-7 cells with 10 μM of BD-PAG
upon LED light irradiation. MCF-7 cells with no irradiation and treatment classified as
100%. (N=6).
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3.3 Materials and Methods
3.3.1 Materials and General Equipments
BD-PAG was synthesized according to our previous reported procedures. All other
reagents and solvents were purchased from commercial suppliers and used without
further purification. UV-vis absorption spectra, mitochondrial pH and potential were
recorded on a Tecan Infinite M200 PRO plate reader spectrometer. Fluorescence
emission spectra were measured using an FLS980 fluorescence spectrometer. Cell images
were recorded on an Olympus IX-81 DSU microscope equipped with a Hamamatsu
EMCCD C9100 digital camera. Z-stack cell images were captured by a Zeiss confocal
microscope. All the cell images were issued by Fiji, a freely available image processing
software.

3.3.2 Cell Culture
Human cervical cancer cell HeLa and human breast cancer cell MCF-7 cell lines were
cultured in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% fetal
bovine serum, 1% penicillin/streptomycin at 37 °C in a humidified 5% CO 2 incubator.
3.3.3 Dark Cell Viability
To assess the cytotoxicity of BD-PAG, HeLa cells and MCF-7 cells were cultured in the
Dulbecco’s modified Eagle’s medium (DMEM) cell medium supplemented with 10%
fetal bovine serum, 1% penicillin, and streptomycin at 37 °C and 5% CO 2. Cells were
placed in 96 well plates and incubated until there were no fewer than 5 × 103 cells per
well for the experiments. Next, cells were incubated with different concentrations of BDPAG (1, 2.5, 5, 10, 20, 40 and 80 μM) 24 h, where the values within parentheses refer to
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the nominal concentrations of the surfactants. After 22 h incubation, 20 μL of the Cell
Titer 96 Aqueous One solution reagent (for MTS assay) was added into each well,
followed by further incubation for 2 h at 37 °C.
The respective absorbance values were read on a Tecan Infinite M200 PRO plate
reader spectrometer at 490 nm. Cell viabilities were calculated based on of the following
equation

Cell Viability  %  

Abs s 490 nm  Abs D 490 nm
100%
Abs c 490 nm  Abs D 2 490 nm

(3.1)

where Abss490nm is the absorbance of the cells incubated with different concentrations of
experimental probe solutions, AbsD490nm is the absorbance of cell-free well containing
only BD-PAG at the concentration that was studied, Absc490nm is the absorbance of cells
alone incubated in the medium, AbsD2 490nm is the absorbance of the cell-free well.

3.3.4 Time Dependent Cell Viability and Combined drug therapy
To assess the photolysis cytotoxicity of BD-PAG, cells were placed in 96 well plates and
incubated until there were no fewer than 5 × 10 3 cells per well for the experiments. Next,
cells were incubated with 10 μM and 20 μM of BD-PAG separately for 4 h. Then, BDPAG was removed and regular DMEM was added for further incubation. After that, cells
were placed under the 595 nm LED lamp (power density ~80 mW/cm 2) with 1 cm
distance for various irradiation time (0, 5, 10, 20 min). Then chlorambucil was added in
chlorambucil + BD-PAG group and an additional 22 h incubation was performed after
the irradiation, except control group which had no BD-PAG or chlorambucil treatment.
And chlorambucil group had not incubate with BD-PAG. 20 μL of the Cell Titer 96
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Aqueous One solution reagent (for MTS assay) was added into each well, followed by
further incubation for 2 h at 37 °C.
The respective absorbance values were read on a Tecan Infinite M200 PRO plate
reader spectrometer at 490 nm. Cell viabilities were calculated based above equation.
3.3.5 Cellular Uptake and Colocalization
To investigate the efficiency and specificity of BD-PAG, HeLa and MCF-7 cells were
employed. All cells were seeded on confocal dish (MatTek) at the density of 4 × 10 4 cells
per dish and incubated for 24 h at 37 °C. Stock solutions of BD-PAG dissolved in DMSO
were prepared at a nominal concentration of 10 4 μM. The stock solution was diluted to 2
μM with the DMEM cell medium and freshly placed over cells for 30 min incubation
period. Cells were washed three times with PBS and further incubated with MitoTracker
Green (MT Green), Lysotracker Green (LT Green), or ER-tracker Green (ER Green)
separately before cell imaging. Cells were then washed with PBS three times, and then
the live cell imaging solution (Molecular Probes) was added to confocal dishes.
Fluorescence images were obtained using an inverted Olympus IX70 microscope coupled
with a FITC filter cube (Ex: 482/40; DM: 506; Em: 534/40) for MT green, LT green, or
ER Green, and a TRITC filter cube (Ex: 532/40; Em: 585/40) for BD-PAG. Bright field,
commercial tracker field and BD-PAG field were obtained, and Pearson’s correlation
coefficients were issued by Fiji, freely available image processing software.
3.3.6 Mitochondrial pH Measurement
For measuring the mitochondrial pH, HeLa cells were employed and seeded on petri-dish
at the density of 1 × 10 6 cells per dish and incubated for 24 h at 37 °C. Then, HeLa cells
were incubated with 10 μM of carboxy SNARF-1 AM for 30 min. Cells were washed
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three times with PBS and incubated with 10 and 20 μM of BD-PAG for 4 h respectively.
After washing out the BD-PAG, cells were irradiated various time (0, 10, and 20 min) by
595 nm LED lamp separately. HeLa cells were removed to 96 well plate for measuring
fluorescent intensity at 590 and 650 nm with 488 nm excitation using a Tecan Infinite
M200 PRO plate reader spectrometer.

3.3.7 Mitochondrial Membrane Potential Measurement
For measuring the mitochondrial pH, HeLa cells were employed and seeded on petri-dish
at the density of 1 × 106 cells per dish and incubated for 24 h at 37 °C. Then, HeLa cells
were incubated with 10 and 20 μM of BD-PAG at 37 °C for 4 h respectively. Control
groups were HeLa cells without BD-PAG treatment. Cells were washed three times with
PBS and irradiated various time (0, 10, and 20 min) by 595nm LED lamp separately.
Cells were incubated with 5 μM of JC-1 at 37 °C for 10 min, then JC-1 was washed out.
HeLa cells were transferred to a 96 well plate for measuring fluorescence intensity at 530
and 590 nm with 475 nm excitation using a Tecan Infinite M200 PRO plate reader
spectrometer.
3.3.8 Time Lapse and Z-stack Cell Imaging
To observe mitochondrial morphological changes during the BD-PAG photolysis, HeLa
cells were employed. All cells were seeded on confocal dish (MatTek) at a density of 4 ×
104 cells per dish and incubated for 24 h at 37 °C. HeLa cells were incubated with 10 and
20 μM of BD-PAG for 30 min, respectively. Control groups were HeLa cells without
BD-PAG treatment. Cells were washed three times with PBS and the live cell imaging
solution (Molecular Probes) was added to confocal dishes. BD-PAG was irradiated
directly by the lamp source of the microscope (power density ~ 4.9 W/cm2), and time-
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lapse cell imaging was recorded every 10 s. Z-stack cell imaging was captured by Zeiss
confocal microscope before and after the irradiation.

3.3.9 Caspase 3 and Caspase 9 measurements
To further assess cytochrome c release and caspase 3/9 activation, caspase 3 and caspase
9 assays were performed in HeLa cells. HeLa cells were mounted on petri-dishes at a
density of 1 × 10 6 cells per dish, and incubated for 24 h at 37 °C. Then, cells were
incubated with 10 μM of BD-PAG at 37 °C for 4 h. The blank group was HeLa cells
without BD-PAG treatment. Cells were washed three times with PBS and irradiated
various time (0, 10, and 20 min) by 595 nm LED lamp separately, followed by further
incubation for 18 h. Caspase 3/9 assays using the corresponding kits were performed and
transferred to a 96 well plate for further incubation. Then, 405 nm absorption was
measured Tecan Infinite M200 PRO plate reader spectrometer.

3.4 Conclusion
In conclusion, the mitochondria targetable pH interference was demonstrated using BDPAG under red LED light. We demonstrate the capability of photo-triggered BD-PAG
release proton (H+) to regulate mitochondrial pH. The acidified mitochondria triggered
mitochondrial membrane depolarization. The mitochondrial morphology transition and
caspase cascade activation further demonstrated that mitochondrial pH decrease leads the
MOMP increase in which the depolarization of mitochondrial membrane caused
reinforced MOMP release of cytochrome C to activate apoptosis pathways. Overcoming
cancer chemotherapeutic drug resistance was observed by a combination drug therapy, in
which the drug efficiency of Cbl was significantly enhanced by lowering the
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mitochondrial pH. This study represents a promising strategy to regulate mitochondrial
pH by using a mitochondria-targeted photoacid generator to overcome cancer drug
resistance.
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CHAPTER 4
PHOTO-UNCAGING OF BODIPY OXIME EASTER FOR HISTONE
DEACETYLASES INDUCED APOPTOSIS IN TUMOR CELLS

Photo-removable protecting groups, or caging groups, enable one to regulate the
activities of bioactive molecules in living cells upon light irradiation. The basic idea
behind the caging technique is that molecules of interest can be inactive when protected
with photo-caging functional groups, then, after light irradiation, the molecules of interest
can be freed and act in an intact form. Herein, a new class of BODIPY-based oxime ester
photo-uncaging group was constructed to release aliphatic/aromatic carboxylic acids.
Upon green light (~ 500 nm) irradiation, oxime esters resulted in N–O bond scission to
generate cyano-photoproducts and release cargo molecules. Photophysical properties of
BODIPY-based oxime esters were investigated via ultraviolet−visible absorption and
fluorescence spectroscopy. Further, we constructed a photo-uncaging drug delivery
system to release valporic acid (VPA), a drug that can inhibit histone deacetylases and
induced apoptosis in tumor cells. In vitro study reveals that our photo-uncaging system
exhibited better cellular uptake, biocompatibility, and photo-regulated drug release for
enhanced toxicity in tumor cells.

4.1 Introduction
Photo-removable protecting groups, or caging groups, enable scientists to regulate
the activities of bioactive molecules in living cells upon light irradiation. The basic
idea behind the caging technique is that molecules of interest can be inactive with
photo-caging groups, after light irradiation the molecules of interest can be freed
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and act in an intact form. This approach has been used for drug delivery and
exhibits pinpoint accuracy with light guidance as well as low off-target toxicity. 135137

However, most of the uncaging groups show absorbability in UV-to-blue

region (300–450 nm), which leads to shallow tissue penetration depth and
increased photo toxicity caused by high energy radiance. Thus, there is a strong
need for uncaging groups that operate in longer wavelength windows. 138
Boron-dipyrromethene (BODIPY) derivatives were identified as one of the
potential chromophore for photo-uncaging, which absorbs in the visible region with high
molar extinction coefficient and resistance to photo bleaching. 139, 140 Most of the reported
BODIPY uncaging groups undergo heterolytic C−O or B-O bond cleavage to release the
active molecules (carboxylic acid, amine, and phenol) (Figure 4.1a). For example, Prof.
Urano’s group developed a novel BODIPY uncaging group where B-O bond cleave
(photo elimination reaction) releases the active molecule from the chromophore. 141, 142 In
addition, Smith and winter et al. reported meso-substituted BODIPY dyes that release
acetic acid under green light at wavelength ~500 nm via the dissociation of C-O bond.143
Further, extended conjugation meso-BODIPY was reported for uncaging of active
molecule through C-O bond cleavage with moderate photochemical quantum yield. 144, 145
Meanwhile, in order to improve the photo-uncaging efficiency, halogen (I/Br) substituted
BODIPY has been used, in which the heavy atoms promote intersystem crossing (ISC) to
a triplet surface, and consequently allows more time for uncaging. 146-149 However, the
halogen substitution can encourage reactive oxygen species (ROS), and consequently
interfere with biological samples. Thus, there is a great need to develop photo-uncaging
systems with high uncaging efficiencies.
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Figure 4.1 Schematic representation of (a) reported green light activated C-O and B-O
cleavage photo-uncaging groups, and (b) our new green light activated N-O cleavage
photo-uncaging approach.
The photochemistry of oxime esters was well studied in the literature for a
decade. Direct irradiation of oxime ester resulted in N–O bond scission to generate iminyl
and caged radical pair.150, 151 The generated radical pair in aqueous polar protic solvent,
subsequently abstracts hydrogen from the solvent to release the caged molecule. 152, 153 In
this work, we take advantage of the weak N-O bond of oxime ester to promote the photouncaging via coupling with BODIPY chromophore. With this intension, we designed a
BODIPY oxime ester as a new photon-uncaging platform that can photo-uncage both
aromatic and aliphatic carboxylic acids (Figure 4.1b).
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For the caged cargo molecule, we chose p-methoxy benzoic acid to represent
aromatic acid and valproic acid (VPA) as an example of aliphatic acid. In addition, VPA
is a small fatty acid, primarily used to treat epilepsy and bipolar disorder and to prevent
migraine headaches.154 Recently, VPA was identified as an inhibitor of histone
deacetylase (HDAC), emerging as a potential anticancer agent to induce cell apoptosis. 155,
156

However, preclinical and clinical research indicates that using VPA directly (without

specific targeting) has multiple side effects and even fatal risks.157,

158

Herein, we

demonstrated that our BODIPY oxime ester caged valproic acid (3a) could be used as a
new platform for light guided cancer treatment. We found compound 3a can be uptaken
by cells and accumulate in the areas close to the nucleus. Upon irradiation, 3a can
effectively release VPA (from N-O cleavage) inside tumor cells, and, consequently,
induce apoptosis and lead to tumor cell death.

4.2 Results and Discussion
4.2.1 Synthetic Strategy
First, a BODIPY core was synthesized using a literature method by reacting 3,4,5 trimethoxylbenzaldehyde

with

2,4-dimethylpyrrole. 159

Next,

a

Vilsmeier–Haack

formylation reaction of the BODIPY core gave compound 1 with the aldehyde functional
group , which was then treated with NH 2OH.HCl in EtOH at reflux temperature to yield
BODIPY-oxime parent compound 2. Reaction of 2 with acid chloride derivatives
afforded the corresponding BODIPY oxime esters, 3a and 3b, with caged VPA and pmethoxy benzoyl, respectively. (Figure 4.2)
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Figure 4.2 Synthesis route of BODIPY oxime ester 3a and 3b.
4.2.2 Photophyscial Properties
UV-vis absorption and emission spectra were then measured using BODIPY oxime esters
(3a, 3b) in methanol. The absorption spectra of 3a and 3b show intense peak centered at
507 (ε = 52800 M-1 cm-1) and 516 nm (ε = 57600 M-1 cm-1) (Figure 4.3). With the
emission maximum centered at 521 and 562 nm, respectively. Fluorescence quantum
yields (Φf) were calculated using fluorescein as standard. Φf of 3a and 3b were
determined to be 0.09 and 0.12, respectively. The low Φ f values are attributed to the
presence of 3n–π* in the vicinity of lowest 1π–π* excited state. Hence, inter-system
crossing occurs in competition with fluorescence.159
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Figure 4.3 Normalized absorption and emission spectra of compound 3a and 3b in
methanol.
Table 4.1 Photophysical Properties for Compound 3a and 3b
λabsa
[nm]

λema
[nm]

[M-1cm-1]

3a

507

521

3b

516

562

Sample

εb

Φfluc

τd
[ns]

Φune
[×104]

εΦun

52800

0.09

0.6

7.2

38

57600

0.12

0.7

5.2

30

a

Absorption and emission maxima; b molar absorption coefficients;
fluorescence lifetimes; e photo-uncaging quantum yield.

c

fluorescent quantum yield;

d

Next, the photo-uncaging abilities of BODIPY oxime esters were studied with
UV-vis spectroscopy. We irradiated the BODIPY oxime esters (1.0×10-5 M of 3a and 3b)
in MeOH/H2O (7/3, v/v) solution with LED light (503±30 nm, power density of ~80
mW/cm2 ), and UV-vis spectra were recorded at different time intervals. Decreases of the
absorbance intensities were observed after irradiation, which were attributed to the
photolysis of the compound (Figures 4.4). We measured the photo-uncaging quantum
yields (Φun) for 3a and 3b using a reported procedure,145,

160

and compared with

previously reported BODIPY based photo-uncaging platforms (Φun=1.5–6.3×10-4 for C-O
bond and Φun=3.0×10-4 for B-O bond), the newly synthesized oxime ester photo-uncaging
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quantum yields are 7.2×10 -4, and 5.2×10-4 for compound 3a and 3b, respectively.143, 144,
149

Further, the rate of photo-uncaging was expressed in the function of quantum

efficiency parameter (εΦun), and εΦun values are 38 and 30 for compound 3a and 3b,
respectively. The higher photo-uncaging quantum yield compared with reported ones is
attributed to the weak N-O bond in the oxime ester. The photophysical properties of 3a
and 3b are summarized in Table 4.1.

Figure 4.4 a) UV-Vis spectra of photorelease from compound 3a in MeOH/Water. (7/3
v/v) b) Absorbance at 505 nm Vs time is plotted, for compound 3a. c) UV-Vis spectra of
photorelease from compound 3b in MeOH/Water. (7/3 v/v) d) Absorbance at 505 nm Vs
time is plotted, for compound 3b.

To verify the photo-uncaging reaction process, we then used compound 3a as an
example, and studied the mechanism and kinetics by following the uncaging procedure
with HPLC and 1H NMR. 3a solution in methanol/H2O (7:3 v/v, 1.0 X10 -5 M) was
irradiated with LED light (λ = 50330 nm, ~80 mW/cm2 ), and the photolyase was taken
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at regular intervals of time to HPLC analysis. Before light irradiation (0 min), BODIPY
oxime ester showed a retention time of 5.6 min in HPLC. After 10 min under green LED
light, the major peak shifted to 6.6 min (Figure 4.5). To further confirm the structure of
the photoproduct, we followed the course of the photo-uncaging using 1H NMR. Aqueous
suspension of the photolyase was taken after 10 min of irradiation (λ = 50330 nm, ~80
mW/cm2 ) and was extracted to perform 1H NMR. By comparing the 1H NMR of 3a, and
the photolyase mixture (Figure 4.6), it was observed that the oxime proton of 3a
decreased in intensity at 8.33 ppm. Further, the BODIPY-β-proton of 3a at 6.12 ppm was
decreased in intensity and new signal emerged at 6.18 ppm, which belongs to the photobyproduct of 2-cyano-BODIPY (Figure 4.7). The peaks intensity ratio of the β-protons
(c’ and c, integration ratio 1.5:1) (Figure 4.6) shows that 60% of 3a has been photolysis
to become 2-cyano-BODIPY upon light irradiation of 10 min. In addition, we also
noticed the appearance of a new multiplet at 2.41 ppm, corresponding to the tertiary
proton of the released VPA.
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Figure 4.5 The LC-MS profile of time-dependent photo-uncaging 3a using green LED
(505 nm) irradiation, time point of 0, 10 and 20 min

Figure 4.6 1H NMR spectra of 3a, 2-cyano-BODIPY photo-byproduct and the
photolysate mixture after 10 min irradiation with green LED (λ = 503  30 nm, ~80
mW/cm2 ).
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Figure 4.7 1H, 13C NMR and Mass spectra of 2-cyano-BODIPY photo-byproduct.
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Figure 4.7(Continued) 1H, 13C NMR and Mass spectra of 2-cyano-BODIPY photobyproduct.

4.2.3 Photolysis Analysis
To understand whether the photo-uncaging proceeds through a triplet or singlet excited
state, the Stern−Volmer quenching experiment on the BODIPY oxime ester 3a was
performed by using triplet quencher (TQ) potassium sorbate. Photolysis of 1 × 10 −5 M
solution of 3a was irradiated without or with addition of different concentration of a
triplet quencher (1 and 5 mM). The course of photolysis was monitored by UV-Vis
absorbance spectroscopy and the change in absorbance was plotted against irradiation
time (Figure 4.8). The result showed the rate of photo-uncaging decreased on increasing
amount of TQ, indicating photo-uncaging of oxime ester proceeds partially via the triplet
excited state. Based on the photo-uncaging byproduct and Stern−Volmer quenching
experiment, we suggested a possible mechanism for the photolysis of BODIPY oxime
ester platform by using the structure of 3a as an example. As shown in Figure 4.9,
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irradiation of 3a leads to an excited state (both singlet and triplet), which then undergoes
cleavage of the N−O linkage in BODIPY oxime ester and consequently release the caged

Normalized absorbance

molecule VPA and form the photoproduct of 2-cyano-BODIPY derivative.
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Figure 4.8 Time course of photolysis for the oxime ester 3a in presence of different
amount of triplet quencher potassium sorbate (PS).

Figure 4.9 Possible photo-uncaging mechanism of N-O bond cleavage of 3a and the
formation of 2-cyano-BODIPY as a photo-byproduct.

4.2.4 Cellular Uptake and Cell Imaging
After investigating the mechanism and kinetics of this photo-uncaging platform, we went
on to assess the biological application of light-regulated drug release. Starting from the
cellular uptake, 10 μM of 3a was incubated with HeLa cells for 4 h, as shown in Figure
4.10a, fluorescence signals (Ex: 482/40; DM: 506; Em: 534/40) of 3a were observed in
the cytoplasm, which accumulated close to the nucleus. Furthermore, we tested the cell
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uptake of 3a at a lower concentration (1 μM) and shorter incubation time (1 h) (Figure
4.10b). The cell images showed similar uptake and location, indicating a high cellular
uptake efficiency of 3a, even at low concentration and short incubation duration.

Figure 4.10 a) HeLa cells were incubated with 10 μM of 3a for 4 h, b) HeLa cells were
incubated with 1 μM of 3a for 1 h. DIC is the bright field.

4.2.5 Dark Cell Viability and Photo-toxicity
The dark cytotoxicity of 3a was evaluated in HeLa cells via MTS assay, shown in figure
4.11a. Two groups were performed in HeLa cells in the dark that incu bated with 3a with
or without removing extracellular 3a (washing) at the time point of 4 h. Both of
conditions did not show any acute toxic effects over a range of concentrations, even at the
highest concentration employed of 40 μM, cell viability remained over 90%.
The phototherapeutic efficiency was then measured by testing the irradiation time
dependent cell viability. HeLa cells were incubated with 20 μM of 3a in two groups, with
or without washing at the time point of 4 h. After further incubation of 24 h, LED light
was given with varied irradiation time. As show in Figure 4.11b, cell viabilities of both
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groups were decreased with increased irradiation time, where they showed cell viability
less than 40% after 5 min irradiation, and less than 20% after 10 min. Meanwhile,
untreated control group (with LED light in absence of 3a) exhibits no cytotoxicity even
over 20 min irradiation, the cell viability was remained 100%, which indicates the LED
light exposure itself has negligible damage to the cells. Furthermore, the photo-byproduct
2-cyano-BODIPY of 3a exhibits relatively non-toxic to the cell (Figure 4.12), which
indicates that the therapeutic and toxic effects came from the released VPA. In literature,
VPA inhibits HDAC in vitro in a dose-dependent manner with an IC50 between 0.93 to
2.43 mM when used along for the treatment ovarian cancer. 161, 162 And the IC50 of VPA
for HeLa cells are reported to be around 2 mM.163 Clearly, our strategy of photo-uncaging
exhibits more therapeutic efficiency with lower concentration (20 μM), that is 100 times
lower than IC50 of VPA in HeLa cells. The high therapeutic efficiency of 3a can be
explained by the good cellular uptake ability and the intracellular location around the
nucleus, where HDAC presents the most. Furthermore, the two groups under irradiation
(Figure 4.11b) with or without washing at the time point of 4 h showed no significantly
difference of the cytotoxicity, indicates the major toxic (therapeutic effect) came from the
VPA released inside cytoplasm. Upon irradiation the extracellularly released VPA
exhibited none significant toxicity to cells.
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Figure 4.11 Dark and photo-toxicity of 3a. a) dark cell viability of HeLa after treatment
with 3a in different concentrations, with (red bar) or without (blue bar) removal of
extracellular 3a at 4 h. b) LED (503±30 nm, ~80 mW/cm2) light irradiation time
dependent cell viability of HeLa cells after treatment with 20 μM of 3a with (red line)
and without (blue line) removal of extracellular 3a at 4 h. Control group (green line) is
HeLa cells treated with LED light in the absence of 3a. (HeLa cells without light and 3a
classified as 100%)

68

Figure 4.12 Photo-toxicity of 2-cyano-BODIPY. LED (503±30 nm, ~80 mW/cm2 ) light
irradiation time dependent cell viability of HeLa cells after treatment with 20 μM of 2cyano-BODIPY. HeLa cells with no treatment was classified as 100%. (N=6)

4.3 Methods
4.3.1 Materials
All reagents and solvents were purchased from commercial suppliers and used as
received without further purification. Compound 2 was synthesized according to their
previous reported procedures. 1H and

13

C NMR spectra were carried out in CDCl3

solution on a Bruker AVANCE spectrometer (500 MHz). orbitrap mass spectrometry
analyses were performed in Prof. Hao Chen’s lab, Department of Chemistry and
Environmental Science, New Jersey Institute of Technology (NJIT). Flash column
chromatography was performed on a CombiFlash® Rf+ automated flash chromatography
using RediSep Rf Gold® normal-phase HP silica columns. UV-vis absorption spectra
were recorded on an Tecan Infinite M200 PRO plate reader spectrometer in 1 cm path
length cuvettes. Fluorescence emission spectra were measured using an Edinburgh
FLS980 fluorescence spectrometer. One-photon fluorescence microscopy images were
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recorded on an Olympus IX-81 DSU microscope equipped with a Hamamatsu EMCCD
C9100 digital camera.
4.3.2 Synthesis of BODIPY Core
3,4,5-Trimethoxylbenzaldehyde (1.65 g) and 2,4-dimethylpyrrole (1.6 g) were dissolved
in dry CH2Cl2 (800 mL) under a nitrogen atmosphere. Nine drops of trifluoroacetic acid
(TFA) (about 0.5 mL) were added, and the mixture was stirred at room temperature
overnight. After TLC monitoring showed complete disappearance of the aldehyde, a
solution of 2, 3-dichloro-5, 6-dicyano-1, 4-benzoquinone (DDQ) (1.9 g) in anhydrous
CH2Cl2 (200 mL) was added. This mixture was further stirred for 4 h, and N, Ndiisopropylethylamine (DIPEA) (16 mL) were added under a nitrogen atmosphere. The
solution was stirred at room temperature for 30 min, and BF 3 -OEt2 (20 mL) was
subsequently added. This mixture was stirred for overnight, where upon the complexation
was found to be completed by TLC monitoring. The mixture was washed thoroughly with
water and brine, dried over anhydrous Na 2 SO4, filtered, and evaporated under vacuum.
The crude compound was purified by silica gel column chromatography (eluent:
petroleum ether/ethyl acetate: first 10:1 to final 5:1, increasing the polarity of the solvent)
to give a shiny green powder as the pure BODIPY dye (600 mg). 1 H NMR (500 MHz,
CDCl3): δ : 6.53 (s, 2H); 6.00(s, 2H), 3.92 (s, 3H, OCH 3 -4), 3.83 (s, 6H, 2 × OCH3 -3, 5),
2.56 (s, 6H), 1.53 (s, 6H) ppm.

13

C NMR (126 MHz, CDCl3) δ: 155.6, 154.2, 143.0,

141.3, 138.6, 131.3, 130.1, 121.2, 105.1, 61.3, 56.3, 30.9, 14.2 ppm.
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Figure 4.13 1 H NMR of BODIPY core compound.

Figure 4.14 13 C NMR of BODIPY core compound.
4.3.3 Synthesis of BODIPY Aldehyde (1)
A mixture of DMF (6 mL) and POCl3 (6 mL) was stirred at -5 °C for 30 min, to this
reaction mixture BODIPY core (150 mg) was dissolved in dichloromethane (5 mL), and
the mixture was stirred for 2 h. The crude product was purified using column
chromatography (silica gel, hexane/EtOAc 6/4 v/v) to give BODIPY aldehyde (1) (142
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mg, 89%) as red crystal solid. 1H NMR (500 MHz, CDCl3): δ:10.0 (s, 1H), 6.51 (s, 2H),
6.18 (s, 1H), 3.93 (s, 3H, OCH 3 -4), 3.84 (s, 6H, 2 × OCH 3 -3, 5), 2.82 (s, 3H), 2.62 (s,
3H), 1.81 (s, 3H), 1.60 (s, 3H).

13C

NMR (126 MHz, CDCl3) δ: 206.9, 185.8, 161.7,

156.6, 154.5, 147.2, 143.2, 142.8, 139.1, 134.0, 129.1, 123.9, 104.9, 61.4, 56.4, 30.9,
14.7, 11.5 ppm. HRMS-ESI: C23H25BF2N2O4 , Calculated :443.19482, Found:
[M+H]+:443.19475.

Figure 4.15 1 H NMR of aldehyde BODIPY compound 1.

Figure 4.16 13 C NMR of aldehyde BODIPY compound 1.
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Figure 4.17 MS spectrum of aldehyde BODIPY compound 1.
4.3.4 Synthesis of BODIPY-oxime Parent Compound (2)
Compound 1 (100 mg) and hydroxylamine hydrochloride (41.4 mg) in absolute ethanol
(20.0 mL) were stirred at reflux temperature for 1 h, the residue was purified by column
chromatography (hexane/ethyl acetate (7/3). BODIPY-oxime parent compound 2 was
obtained as red solid (86.0 mg, 70.0% yield). 1H NMR (500 MHz, CDCl 3) δ: 8.01 (s,
1H), 6.52 (s, 2H), 6.08 (s, 1H), 3.93 (s, 3H, OCH 3 -4), 3.83 (s, 6H, 2 × OCH 3-3, 5), 2.70
(s, 3H), 2.58 (s, 3H), 1.62 (s, 3H), 1.55 (s, 3H).

13C

NMR (126 MHz, CDCl3) δ= 158.2,

154.3, 144.8, 142.0, 139.9, 138.9, 130.4, 129.7, 122.4, 121.48, 105.1, 61.4, 56.4, 14.5,
12.3 ppm.
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Figure 4.18 1H NMR of BODIPY compound 2.

Figure 4.19 13C NMR of BODIPY compound 2.
4.3.5 Synthesis of BODIPY Oxime Esters (3a, 3b)
A solution of BODIPY oxime (2) in dry dichloromethane was cooled to 0 ◦C under a
nitrogen atmosphere, triethylamine (0.28 ml) was added followed by acid chloride
(1.2eq) in dry dichloromethane and the mixture was allowed to stir for 4 h allowing the
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temp to slowly rise to 25 °C. The organic phases were then washed with brine and the
residue was purified by column chromatography (hexane/ethyl acetate 7/3 v/v). BODIPY
oxime ester was obtained as red solid in good yield.
(3a): 1H NMR (500 MHz, CDCl3 ) δ: 8.32 (s, 1H), 6.51 (s, 2H), 6.11 (s, 1H), 3.91
(s, 3H, OCH3 -4), 3.83 (s, 6H, 2 × OCH 3-3, 5), 2.75 (s, 3H), 2.59 (s, 3H), 2.51-2.46 (m,
1H), 1.72 (s, 3H), 1.69-1.64 (m, 2H), 1.58 (s, 3H), 1.51-1.48 (m, 2H), 1.47-1.36 (m,
2H), 1.25-0.89(t, 6H). 13 C NMR (126 MHz, CDCl3) δ: 180.6, 173.8, 159.7, 154.4, 150.0,
146.0, 142.4, 140.9, 139.0, 133.0, 130.5, 129.4, 123.1, 119.5, 105.0, 61.4, 60.3, 56.4,
43.9, 34.6, 20.6, 14.6, 13.9 ppm.

C 31H40BF2N3O5 H+ Calculated Mass: 584.3007,

Experimental mass: [M+H]+: 584.3095.

Figure 4.20 1H NMR of BODIPY compound 3a.
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Figure 4.21 13C NMR of BODIPY compound 3a.
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Figure 4.22 MS spectrum of BODIPY compound 3a.
(3b): 1H NMR (500 MHz, CDCl3 ) δ: 8.09 (d, 2H), 6.98 (d, 2H), 6.51 (s, 2H), 6.21
(s, 1H),3.95 (s, 3H, OCH3), 3.90 (s, 3H, OCH 3 -4), 3.87 (s, 6H, 2 × OCH3 -3, 5), 2.69 (s,
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6H), 1.67 (s, 6H).

13C

NMR (126 MHz, CDCl3) δ: 164.6, 162.3, 160.0, 154.4, 148.7,

145.9, 142.0, 139.0, 137.2, 134.4, 132.8, 129.2, 127.8, 122.7, 122.3, 114.1, 104.9, 61 .4,
56.4, 55.6, 29.7, 14.5, 11.4 ppm.

C 31H32BF2N3O6 H+ Calculated Mass: 592.2430,

Experimental mass: [M-F-] +: 572.92718.

Figure 4.23 1H NMR of BODIPY compound 3b.
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Figure 4.24 13C NMR of BODIPY compound 3b.

4.3.6 Photophysical Property Measurement
All steady-state absorption, fluorescence emission, of compound 3a and 3b were
investigated in 10 mm path length quartz cuvettes at room temperature. The steady-state
absorption was measured with Tecan Infinite M200 PRO plate reader spectrometer in 1
cm path length cuvettes. Fluorescence emission and excitation spectra were obtained
using an Edinburgh Photonics FLS980spectrometer equipped with a thermoelectric
cooled photo multiplier detector (Hamamatsu) and a liquid-nitrogen cooled NIRphotomultiplier detector (Hamamatsu). All measurements were carried out with the
optical density below 0.12 at the excitation wavelength to avoid reabsorption. The
excitation and fluorescence emission spectra were corrected for the spectral sensitivity of
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Edinburgh Photonics excitation and detection system using factory-measured correction
files. Fluorescence lifetimes (τF) were determined with the single photon counting
technique (TCSPC) and the same fluorescence spectrometer using a pulsed picosecond
diode laser (EPL-505) as the excitation source. Molar absorption coefficients (ε) and
maximum absorbance wavelengths (λ max) were determine in acetonitrile using Beer’s
law, from plots of absorbance vs. concentration. Recordings were performed in 10 mm
path length quartz cuvettes at room temperature.
Fluorescence quantum yields were determined by a reference point method.
Fluorescein as standard / exe at 496nm in 0.1 M NaOH (f) =0.95 was used as a standard
sample

to

calculate

the

QY

of

3a

and

3b.

The

equation

as

follow:

(4.1)

s
R

=

As

(Abs)R s2

AR

(Abs)s R2

where Φ represents quantum yield, Abs represents absorbance, A represents area under
the fluorescence curve, and η is refractive index of the medium. The subscripts S and R
denote the corresponding parameters for the sample and reference, respectively.
Compound 3a (2 mL of 1×10–5 M in MeOH/Water (7/3 v/v) and Compound 3b (2
mL of 1×10–5 M in MeOH/Water (7/3 v/v)) was placed in quartz cuvette (10 mm path).
Further the photolysis was followed by biological condition also Compound 3a (2 mL of
1×10–5 M in PBS/DMSO (9.5/0.5 v/v)) was placed in quartz cuvette (10 mm path). The
cuvette was placed in front of a light source (Thorlab’s M505L3) mounted LED has a
nominal wavelength 503 ± 30 nm with a power density of ≈ 80 mW/cm 2 , at 1 cm distance
and irradiated for the indicated times. At regular interval of time point, the cuvette was
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analysis by UV-Vis spectrophotometer. The photochemical stability was investigated
quantitatively by measuring the photochemical decomposition quantum yield,
Φph=Nph/N hv (Nph and N hv are the numbers of decomposed molecules and absorbed
photons, respectively). The values of Φph were determined by an absorption method using
a mounted LED for excitation of the compound 3a and 3b (excitation wavelength ≈ 503
nm, average beam irradiance ≈ 80 mW/cm2). According to the well-developed absorption
methodology, the values of Φph can be determined by the following equation:
Φph = (At − A0)N A/103 × ε × I×[1−10(At+A0 )/2 ]× t

(4.2)

At and A0 are absorbance maximum at time points t and t 0 , respectively. NA is
Avogadro’s number, ε is the molar extinction coefficient (M -1 cm-1), I is the irradiation
intensity (photon cm-2 s - 1), and t is the irradiation time (sec).
5 mL of Compound 3a (1×10–5 M) in MeOH/Water (7/3 v/v)) solution was placed
in quartz cuvette (10 mm path). They were irradiated under mounted LED has a
wavelength of 503  30nm with the output power of ≈ 80 mW/cm2. At regular interval of
time, 50 µL of the aliquots was taken and analyzed by LC-MS using mobile phase
acetonitrile/water (95/5 v/v), at a flow rate of 0.1 mL/min (detection: UV at wavelength
of 500 nm). The reaction was followed until the consumption of the caged oxime ester of
the initial area. The peak areas were determined by LC, which indicated gradual increase
of peak area with time.
We also have followed the course of the photorelease by 1H NMR spectroscopy.
A known amount (1 mL) of aqueous suspension of the photolysate was taken at regular
intervals of time and was extracted in dichloromethane (DCM), then solvent was
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evaporated under vacuum and re-dissolved in CDCl 3 and the 1H NMR was recorded. 1H
NMR spectra showed a clean photocleavage of the 3a into corresponding photoproducts.
4.3.7 Preparative Photolysis
5 mg of Compound 3a in MeOH/Water (7/3 v/v)) solution were irradiated under mounted
LED has a wavelength of 503  30 for 10 min. At regular interval of time, the reaction
was monitored by TLC. After completion of reaction the photoproduct was isolated using
preparative TLC using 15% EtOAc as a mobile phase. The photoproduct of 2-cyanoBODIPY was analyzed by 1H, 13 C NMR and mass analysis. 1H NMR (500 MHz, CDCl3)
δ: 6.49 (s, 2H), 6.18 (s, 1H), 3.93 (s, 3H, OCH3-4), 3.87 (s, 6H, 2 × OCH3-3, 5), 2.662.62(s, 6H), 1.65-1.61 (s, 6H).

13

C NMR (126 MHz, CDCl3) δ: 163.37, 154.94, 148.37,

143.01, 139.61, 134.68, 130.76, 129.05, 124.64, 115.32, 114.47, 105.12, 61.79, 56.86,
30.08, 15.57, 15.11. C23H24BF2N3 O3H+ Calculated Mass: 440.1951, Experimental mass:
440.1948.
4.3.8 Cell Culture and Cellular Uptake
HeLa cell line was cultured in Dulbecco's Modified Eagle Medium (DMEM)
supplemented with 10% fetal bovine serum, 1% penicillin/streptomycin at 37 °C in a
humidified 5% CO 2 incubator. To investigate the cellular of BDVPA, HeLa cells were
employed. All cells were seeded on confocal dish (MatTek) at the density of 4 × 10 4 cells
per dish and incubated for 24 h at 37 ℃. Stock solutions of 3a dissolved in DMSO were
prepared at a nominal concentration of 10 4 μM. The stock solution was diluted to 1 and
10 μM with the DMEM cell medium respectively and freshly placed over cells for 1 h
and 4 h incubation period separately. Cells were washed three times with PBS and the
live cell imaging solution (Molecular Probes) was added to confocal dishes. Fluorescent
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images were obtained using an inverted Olympus IX70 microscope coupled with a FITC
filter cube (Ex: 482/40; DM: 506; Em: 534/40). Bright field was obtained and 3a
fluorescent images were obtained and issued by Fiji, freely available image processing
software.
4.3.9 Cell Viability and Photolysis Cytotoxicity
To assess the cytotoxicity of 3a, HeLa cells were cultured in the Dulbecco’s modified
Eagle’s medium (DMEM) cell medium supplemented with 10% fetal bovine serum, 1%
penicillin, and streptomycin at 37 °C and 5% CO 2. Cells were placed in 96 well plates
and incubated until there were no fewer than 5 × 10 3 cells per well for the experiments.
Next, cells were incubated with different concentrations of 3a (0.1, 0.5, 1, 2.5, 5, 10, 20,
40 μM) 4 h, where the values within parentheses refer to the nominal concentrations of
the surfactants. Then, 3a was removed and regular DMEM was added for 4 h washed +
24 h group, additional 22 h incubation was performed for both 4 h washed + 24 h and 4 h
+24 h groups. After 22 h incubation, 20 μL of the Cell Titer 96 Aqueous One solution
reagent (for MTS assay) was added into each well, followed by further incubation for 2 h
at 37 °C. The respective absorbance values were read on a Tecan Infinite M200 PRO
plate reader spectrometer at 490 nm. Cell viabilities were calculated based on the
following equation:
𝑆
𝐷
𝐴𝑏𝑠490𝑛𝑚
− 𝐴𝑏𝑠490𝑛𝑚
𝐶𝑒𝑙𝑙 𝑉𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 (%) =
× 100%
𝐶
𝐷2
𝐴𝑏𝑠490𝑛𝑚
− 𝐴𝑏𝑠490𝑛𝑚

(4.3)

where AbsS 490nm is the absorbance of the cells incubated with different concentrations of
experimental solutions, AbsD490nm is the absorbance of cell-free well containing only dye
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at the concentration studied, AbsC490nm is the absorbance of cells only incubated in
medium, and AbsD2490nm is the absorbance of the cell-free well.
To assess the photolysis cytotoxicity of 3a and the photo-byproduct 2-cyanoBODIPY, HeLa cells were cultured in the Dulbecco’s modified Eagle’s medium (DMEM)
cell medium supplemented with 10% fetal bovine serum, 1% penicillin, and streptomycin
at 37 °C and 5% CO2. Cells were placed in 96 well plates and incubated until there were
no fewer than 5 × 10 3 cells per well for the experiments. Next, cells were incubated with
20 μM of 3a and 2-cyano-BODIPY separately for 4 h, except control group which had no
treatment. Then, 3a was removed and regular DMEM was added for further incubation
without 3a group. After that, control, 2-cyano-BODIPY, further incubation with 3a group,
and further incubation without 3a group were placed under the 505 nm LED lamp for
various irradiation time (1, 3, 5, 10, 20 min). And an additional 22 h incubation was
performed after the irradiation. 20 μL of the Cell Titer 96 Aqueous One solution reagent
(for MTS assay) was added into each well, followed by further incubation for 2 h at
37 °C. The respective absorbance values were read on a Tecan Infinite M200 PRO plate
reader spectrometer at 490 nm. Cell viabilities were calculated on the basis of above
equation.

4.4 Conclusion
In conclusion, we have developed a new BODIPY oxime ester photo-uncaging platform
for light guided delivery of compounds containing carboxylic acid. The photochemistry
and photo-physics of the uncaging were studied, and a possible photo-uncaging
mechanism was proposed by identifying the structure of photo-byproduct. We
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demonstrated that we can photo-uncage an anti-cancer drug (VPA) and observed
enhanced therapeutic effects due to the increased cell uptake and localized release.
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